Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of “Hold” by Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has earned a consensus rating of “Hold” from the twenty-one ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $124.11.

Several research firms have recently commented on ZBH. Barclays decreased their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Oppenheimer decreased their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada raised their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors have recently modified their holdings of ZBH. Equity Investment Corp bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after acquiring an additional 577,320 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after acquiring an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $41,588,000. Finally, FMR LLC lifted its stake in shares of Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after acquiring an additional 162,384 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.4 %

ZBH stock opened at $108.27 on Thursday. Zimmer Biomet has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The business’s 50-day moving average is $107.82 and its two-hundred day moving average is $108.20. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market cap of $21.55 billion, a price-to-earnings ratio of 20.58, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.